Annovis Bio, Inc. is a clinical-stage American biotechnology company headquartered in Berwyn, Pennsylvania, focused on developing novel treatments for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The company's lead compound, bunodimod (formerly Annovis-101), targets multiple neurotoxic proteins.
| Attribute | Details |
|-----------|---------|
| Ticker | NYSE: ANVS |
| Headquarters | Berwyn, Pennsylvania, USA |
| Founded | 2009 (as ALLERVIS, renamed 2019) |
| CEO | Maria Maccecchini |
| Employees | ~20 |
| Market Cap | ~$50 million (2024) |
| Drug |
Mechanism |
Phase |
Indication |
| Bunodimod |
Sigma-1 agonist / mTOR inhibitor |
Phase 2/3 |
AD, PD |
- Mechanism: Sigma-1 receptor agonist and mTOR inhibitor
- Targets: Sigma-1 receptor, mTOR pathway
- Phase: Phase 2/3 (NCT05514170 for AD, NCT04577352 for PD)
- Status: Recruiting
- Clinical Trials:
Bunodimod is a small molecule with dual mechanism:
- Sigma-1 Receptor Agonism: Modulates ER stress response, mitochondrial function, and calcium homeostasis
- mTOR Inhibition: Reduces translation of neurotoxic proteins (APP, alpha-synuclein)
The company claims this "single molecule, multiple targets" approach addresses multiple pathologies simultaneously:
- Study: Placebo-controlled, randomized
- Population: Early AD patients
- Primary Endpoint: Change in cognition (ADAS-Cog)
- Status: Recruiting (as of 2024)
- Reduced amyloid-beta in animal models
- Improved cognition in AD mouse models
- Study: Placebo-controlled, randomized
- Population: Early PD patients
- Primary Endpoint: Change in motor symptoms (MDS-UPDRS)
- Status: Recruiting (as of 2024)
- Reduced alpha-synuclein aggregation
- Improved motor function in PD models
| Drug |
Mechanism |
Phase |
| ANAVEX 2-73 |
Sigma-1 agonist |
Phase 2/3 |
| ANAVEX 1-41 |
Sigma-1 agonist |
Phase 1 |
| ANAVEX 3-71 |
Sigma-1 agonist |
Preclinical |
- Mechanism: Sigma-1 receptor agonist
- Phase: Phase 1 (completed)
- Indication: Depression/anxiety
- Mechanism: Sigma-1 and Sigma-2 agonist
- Phase: Preclinical
- Rationale: Dual sigma receptor modulation
The company's approach is based on the "multiple hit" hypothesis of neurodegeneration:
- Multiple proteins become dysregulated in neurodegenerative diseases
- Targeting a single protein may not be sufficient
- Sigma-1 receptor modulation affects multiple pathways
| Year |
Revenue |
Cash |
Key Programs |
| 2023 |
$0 |
$30M |
Bunodimod |
| 2022 |
$0 |
$40M |
Bunodimod |
| 2021 |
$0 |
$50M |
Bunodimod |
- Maria Maccecchini - CEO and Founder
- Cameron - CMO
- Pat - CSO